Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial.

Benton TD.

Curr Psychiatry Rep. 2011 Apr;13(2):77-9. doi: 10.1007/s11920-010-0172-0. No abstract available.

PMID:
21286868
2.

Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.

Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F.

J Autism Dev Disord. 2007 Feb;37(2):367-73.

PMID:
17019624
3.

Aripiprazole: new drug. Just another neuroleptic.

[No authors listed]

Prescrire Int. 2005 Oct;14(79):163-7.

PMID:
16285069
4.
5.

Controlled trials of inositol in psychiatry.

Levine J.

Eur Neuropsychopharmacol. 1997 May;7(2):147-55.

PMID:
9169302
6.

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.

McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH.

Arch Gen Psychiatry. 1998 Jul;55(7):633-41.

PMID:
9672054
7.

Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.

King BH, Wright DM, Handen BL, Sikich L, Zimmerman AW, McMahon W, Cantwell E, Davanzo PA, Dourish CT, Dykens EM, Hooper SR, Jaselskis CA, Leventhal BL, Levitt J, Lord C, Lubetsky MJ, Myers SM, Ozonoff S, Shah BG, Snape M, Shernoff EW, Williamson K, Cook EH Jr.

J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):658-65.

PMID:
11392343
8.

Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.

Wymer JP, Simpson J, Sen D, Bongardt S; Lacosamide SP742 Study Group..

Clin J Pain. 2009 Jun;25(5):376-85. doi: 10.1097/AJP.0b013e318196d2b6.

PMID:
19454870
9.

Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women.

Steiner M, Ravindran AV, LeMelledo JM, Carter D, Huang JO, Anonychuk AM, Simpson SD.

J Clin Psychiatry. 2008 Jun;69(6):991-8.

PMID:
18517289
10.

Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.

Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW.

N Engl J Med. 1999 Dec 9;341(24):1801-6.

11.

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, Ghanizadeh A, Raznahan M, Mohebbi-Rasa S, Rezazadeh SA, Forghani S.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):32-6. doi: 10.1016/j.pnpbp.2009.09.012. Epub 2009 Sep 20.

PMID:
19772883
12.

Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.

Akhondzadeh S, Erfani S, Mohammadi MR, Tehrani-Doost M, Amini H, Gudarzi SS, Yasamy MT.

J Clin Pharm Ther. 2004 Apr;29(2):145-50.

PMID:
15068403
13.

Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.

Wagg A, Wyndaele JJ, Sieber P.

Am J Geriatr Pharmacother. 2006 Mar;4(1):14-24.

PMID:
16730617
14.

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.

Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group..

J Hypertens. 2005 Dec;23(12):2157-72.

PMID:
16269957

Supplemental Content

Support Center